Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Hernandez

Internal Medicine Shreveport, LA Medical Doctor

NPI 1043247745 CMS profile 1047786

1800 Irving Place, Suite 450, Shreveport, LA 71101

Open in the dashboard

General payments

$5,718

373 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Hernandez of Shreveport, LA is reported in the CMS Open Payments database as having received $5,718 across 373 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $95 4
2024 General $91 5
2023 General $1,401 78
2022 General $1,178 87
2021 General $1,098 91
2020 General $953 58
2019 General $902 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Hernandez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Hernandez were reported at $95. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Hernandez Internal Medicine median Middle half National median
2019 $902 $159 $48–$570 $163
2020 $953 $119 $33–$402 $114
2021 $1,098 $135 $37–$521 $132
2022 $1,178 $141 $42–$496 $149
2023 $1,401 $149 $45–$519 $160
2024 $91 $154 $47–$537 $164
2025 $95 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $1,664 103 payments
  2. Amgen Inc. $492 20 payments
  3. ACADIA Pharmaceuticals Inc $331 18 payments
  4. AbbVie, Inc. $323 57 payments
  5. Novo Nordisk Inc $321 20 payments
  6. Lilly USA, LLC $292 19 payments
  7. AstraZeneca Pharmaceuticals LP $268 12 payments
  8. Pfizer Inc. $221 13 payments
  9. Merck Sharp & Dohme Corporation $209 14 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $199 15 payments
  11. Other $1,400 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,712 372 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. INJECTAFER Iron Deficiency Anemia $1,188 76 payments
  2. INJECTAFER Anemia $469 26 payments
  3. Prolia $297 14 payments
  4. Repatha $223 8 payments
  5. NUPLAZID $218 11 payments
  6. RYBELSUS $212 12 payments
  7. XIFAXAN $199 15 payments
  8. Ozempic $197 11 payments
  9. VERQUVO $180 12 payments
  10. NUEDEXTA $179 10 payments
  11. Other $3,794 274 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 228 drugs

Part D claims

17,516

Median for Internal Medicine: 777

Drug cost

$1,125,225

Median for Internal Medicine: $73,373

Branded share of claims

22.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 529 $167,781
Avonex Pen (4 Pack) Interferon Beta-1a Brand 13 $113,529
Trulicity Dulaglutide Brand 56 $53,416
Ozempic Semaglutide Brand 39 $43,625
Invega Sustenna Paliperidone Palmitate Brand 21 $43,124
Xarelto Rivaroxaban Brand 87 $38,823
Tresiba Flextouch U-100 Insulin Degludec Brand 88 $35,382
Januvia Sitagliptin Phosphate Brand 114 $34,290
Linzess Linaclotide Brand 50 $29,053
Jardiance Empagliflozin Brand 65 $25,659

The 10 drugs with the highest cost, of 228 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$267,459

Medicare's payments for the services billed

Medicare patients

886

Average age 79

Services billed

3,413

566 women, 320 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Depression 65%
Diabetes 62%
Alzheimer's or dementia 57%
Ischemic heart disease 43%
Heart failure 41%
Chronic kidney disease 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $38
$38 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $36
$36 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record